Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?

Area of Science:

• Pharmacology
• Infectious Diseases
• Health Policy

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat.
• The Generating Antibiotic Incentives Now Act (GAIN Act) was established in 2012 to stimulate the development of new antimicrobial drugs.
• Qualified Infectious Disease Products (QIDPs) under the GAIN Act receive benefits like extended market exclusivity.

Purpose of the Study:

• To evaluate the effectiveness of the GAIN Act in incentivizing novel antimicrobial drug development.
• To identify limitations in the current QIDP eligibility criteria and their impact on drug development.
• To propose improvements to the GAIN Act to better address unmet medical needs in infectious diseases.

Main Methods:

• Analysis of the outcomes of the GAIN Act program since its inception.
• Assessment of the QIDP eligibility criteria in relation to unmet medical needs.
• Economic evaluation of the time value of money in the context of QIDP exclusivity benefits.

Main Results:

• The GAIN Act program has shown disappointing results to date.
• Current QIDP eligibility criteria are not adequately focused on addressing critical unmet needs.
• The economic structure of QIDP exclusivity disproportionately favors modifications of existing drugs over novel therapeutics.

Conclusions:

• The GAIN Act requires modification to effectively incentivize the development of new antimicrobial treatments.
• Narrowing the list of qualifying pathogens for QIDP designation is crucial.
• Enhancements such as increased reliance on animal data and companion diagnostics could improve the program's efficacy.